SCHEMBL2739092

SCHEMBL2739092

Fc1ccc(-n2cc(C3CCNCC3)c3cc(Cl)ccc32)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 9/20 1.00
MLNR O43193 1/20 0.63
CACNA1F O60840 1/20 0.63
NR1I2 O75469 1/20 0.63
ABCB11 O95342 1/20 0.63
ABCB1 P08183 1/20 0.63
ADRB1 P08588 1/20 0.63
HTR1A P08908 1/20 0.63
ADRA2A P08913 1/20 0.63
ADORA3 P0DMS8 1/20 0.63
CHRM1 P11229 1/20 0.63
DRD2 P14416 1/20 0.63
ADRA2B P18089 1/20 0.63
ADRA2C P18825 1/20 0.63
CHRM3 P20309 1/20 0.63
MAOA P21397 1/20 0.63
CNR1 P21554 1/20 0.63
DRD1 P21728 1/20 0.63
DRD4 P21917 1/20 0.63
KCNA5 P22460 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27817823 0.99 KCNH2 (0.98) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL9150576 0.90 KCNH2 (0.82) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL8640342 0.90 KCNH2 (0.81) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL6599893 0.85 KCNH2 (0.74) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL8642973 0.84 KCNH2 (0.73) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL8240493 0.84 KCNH2 (0.73) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL6967113 0.83 KCNH2 (0.71) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL17510363 0.82 KCNH2 (0.73) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL7337112 0.80 KCNH2 (0.70) KCNH2MLNRCACNA1FNR1I2ABCB11
SCHEMBL8638064 0.80 KCNH2 (0.70) KCNH2MLNRCACNA1FNR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1243001-C Process for the manufacture of sertindole LUNDBECK & CO AS H (DK) 2006-02-22 CN claimed
EP-1260511-B1 Process for the preparation of 5-chloro-1-(4-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)indole and method of manufacturing sertindole LUNDBECK & CO AS H (DK) 2004-12-29 EP claimed
EP-0983264-B1 METHOD OF MANUFACTURING SERTINDOLE LUNDBECK & CO AS H (DK) 2004-02-04 EP claimed
EP-1260511-A1 Process for the preparation of 5-chloro-1-(4-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)indole and method of manufacturing sertindole H. Lundbeck A/S (DK) 2002-11-27 EP claimed
US-6335463-B1 Method of manufacturing sertindole H. LUNDBECK A/S (DK) 2002-01-01 US claimed
CN-1261363-A Process for the manufacture of sertindole LUNDBECK & CO AS H (DK) 2000-07-26 CN claimed
CN-101899036-B Method for preparing sertindole by using alkyl imidazole type ionic liquid as solvent UNIV ZHENGZHOU 2012-12-19 CN disclosed
US-8088918-B2 Noncardiotoxic pharmaceutical compounds WILLIAMSBURG HOLDINGS LLC (US) 2012-01-03 US disclosed
US-8088918-B2 Noncardiotoxic pharmaceutical compounds WILLIAMSBURG HOLDINGS LLC (US) 2012-01-03 US disclosed
CN-101899036-A Method for preparing sertindole by using alkyl imidazole type ionic liquid as solvent UNIV ZHENGZHOU 2010-12-01 CN disclosed
CN-101362749-A Sertindole synthesis method SHANGHAI INST PHARM INDUSTRY (CN) 2009-02-11 CN disclosed
US-20070212412-A1 STABLE SOLID FORMULATION OF SERTINDOLE H. LUNDBECK A/S (DK) 2007-09-13 US disclosed
US-20070212412-A1 STABLE SOLID FORMULATION OF SERTINDOLE H. LUNDBECK A/S (DK) 2007-09-13 US disclosed
EP-0726898-A1 PHENYLINDOLE COMPOUNDS H. LUNDBECK A/S (DK) 1996-08-21 EP disclosed
EP-0575429-B1 TREATMENT OF COGNITIVE DISORDERS LUNDBECK & CO AS H (DK) 1995-12-06 EP disclosed
US-5462948-A Treatment of addiction to drugs and substances of abuse H. LUNDBECK A/S (DK) 1995-10-31 US disclosed
US-5444073-A Administering 1-aryl-3-(4-piperidyl)-indole derivatives H. LUNDBECK A/S (DK) 1995-08-22 US disclosed
US-5439922-A Administering dopamine antagonists having reduced side effects H. LUNDBECK A/S (DK) 1995-08-08 US disclosed
WO-1995012591-A1 PHENYLINDOLE COMPOUNDS H. LUNDBECK A/S (DK) 1995-05-11 WO disclosed
EP-0533824-B1 PIPERIDYL-SUBSTITUTED INDOLES LUNDBECK & CO AS H (DK) 1994-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070212412-A1 STABLE SOLID FORMULATION OF SERTINDOLE TPH2, TPH1, SLC6A4 KCNH2 182/4885MLNR 1195/4885CACNA1F 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.